Shares of Vectura Group PLC (LON:VEC) have received a consensus recommendation of “Buy” from the nine brokerages that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is GBX 211.29 ($2.75).
A number of analysts have weighed in on the company. Numis Securities Ltd restated a “buy” rating and set a GBX 214 ($2.79) target price on shares of Vectura Group PLC in a report on Thursday, June 29th. N+1 Singer restated a “hold” rating on shares of Vectura Group PLC in a report on Thursday, June 29th. Peel Hunt restated a “hold” rating and set a GBX 160 ($2.08) target price on shares of Vectura Group PLC in a report on Thursday, June 29th. J P Morgan Chase & Co lowered their target price on Vectura Group PLC from GBX 240 ($3.13) to GBX 210 ($2.74) and set an “overweight” rating for the company in a report on Friday, May 12th. Finally, Royal Bank Of Canada lowered Vectura Group PLC to an “underperform” rating in a report on Tuesday, April 25th.
COPYRIGHT VIOLATION NOTICE: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/07/31/brokerages-set-vectura-group-plc-lonvec-pt-at-211-29.html.
Vectura Group PLC (LON:VEC) opened at 116.00 on Friday. Vectura Group PLC has a 52-week low of GBX 109.50 and a 52-week high of GBX 166.97. The company’s market cap is GBX 786.08 million. The company’s 50-day moving average price is GBX 113.48 and its 200-day moving average price is GBX 133.62.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.
